Blood purification · 2024
Peritoneal Glucose Uptake Reduction by Sodium-Glucose Co-Transporter 2 Inhibitors in Clinical Peritoneal Dialysis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kasai Takahiro, Iida Yoshito, Kimura Takahide, Tanemoto Masayuki
Аннотация
INTRODUCTION: In peritoneal dialysis (PD), managing peritoneal glucose uptake is a clinical challenge, as the uptake leads to peritoneal ultrafiltration loss. Peritoneal expression of sodium-glucose co-transporter 2 (SGLT2) suggests that SGLT2 inhibitors, a class of antidiabetic agents, may offer a solution.
METHODS: In 12 PD patients, we examined the influence of dapagliflozin, an SGLT2 inhibitor, on peritoneal equilibration test.
RESULTS: The volume of drainage and the total glucose content in drainage were larger in the test with dapagliflozin than in that without dapagliflozin (2.41 ± 0.16 vs. 2.23 ± 0.20 L, p = 0.011 and 16.9 ± 3.8 vs. 14.5 ± 3.7 g, p = 0.005, respectively).
CONCLUSION: SGLT2 inhibitors could reduce peritoneal glucose uptake and improve fluid removal in clinical PD.
METHODS: In 12 PD patients, we examined the influence of dapagliflozin, an SGLT2 inhibitor, on peritoneal equilibration test.
RESULTS: The volume of drainage and the total glucose content in drainage were larger in the test with dapagliflozin than in that without dapagliflozin (2.41 ± 0.16 vs. 2.23 ± 0.20 L, p = 0.011 and 16.9 ± 3.8 vs. 14.5 ± 3.7 g, p = 0.005, respectively).
CONCLUSION: SGLT2 inhibitors could reduce peritoneal glucose uptake and improve fluid removal in clinical PD.